A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants

NCT06627556 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-10-04

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of H021 tablets following oral administration of single and multiple ascending doses in healthy participants.

Conditions

Interventions

DRUG

H021

H021 oral tablet.

DRUG

H021 Placebo

H021 placebo oral tablet.

Sponsors & Collaborators

  • Jiangsu Carephar Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-17
Primary Completion
2025-02-27
Completion
2025-02-27

Countries

  • Australia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06627556 on ClinicalTrials.gov